A detailed history of Prudential Financial Inc transactions in Allogene Therapeutics, Inc. stock. As of the latest transaction made, Prudential Financial Inc holds 214,495 shares of ALLO stock, worth $527,657. This represents 0.0% of its overall portfolio holdings.

Number of Shares
214,495
Previous 231,896 7.5%
Holding current value
$527,657
Previous $540,000 11.11%
% of portfolio
0.0%
Previous 0.0%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

SELL
$2.08 - $3.5 $36,194 - $60,903
-17,401 Reduced 7.5%
214,495 $600,000
Q2 2024

Aug 13, 2024

BUY
$2.23 - $4.38 $74,669 - $146,659
33,484 Added 16.88%
231,896 $540,000
Q1 2024

May 14, 2024

SELL
$2.92 - $5.63 $526,849 - $1.02 Million
-180,428 Reduced 47.63%
198,412 $886,000
Q4 2023

Feb 13, 2024

BUY
$2.28 - $3.5 $863,755 - $1.33 Million
378,840 New
378,840 $1.22 Million
Q2 2023

Aug 11, 2023

SELL
$4.53 - $6.74 $247,070 - $367,606
-54,541 Reduced 61.68%
33,890 $168,000
Q1 2023

May 12, 2023

BUY
$4.92 - $8.21 $435,080 - $726,018
88,431 New
88,431 $436,000
Q1 2021

May 12, 2021

SELL
$25.79 - $39.02 $2.63 Million - $3.98 Million
-102,036 Closed
0 $0
Q4 2020

Feb 16, 2021

BUY
$25.24 - $43.45 $2.57 Million - $4.43 Million
102,008 Added 364314.28%
102,036 $2.58 Million
Q3 2020

Aug 05, 2021

SELL
$32.38 - $44.96 $8.56 Million - $11.9 Million
-264,326 Reduced 99.99%
28 $1,000
Q3 2020

Nov 16, 2020

BUY
$32.38 - $44.96 $8.04 Million - $11.2 Million
248,209 Added 1537.37%
264,354 $9.97 Million
Q2 2020

Aug 12, 2020

BUY
$18.39 - $54.04 $296,906 - $872,475
16,145 New
16,145 $691,000

Others Institutions Holding ALLO

About Allogene Therapeutics, Inc.


  • Ticker ALLO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 143,807,008
  • Market Cap $354M
  • Description
  • Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult p...
More about ALLO
Track This Portfolio

Track Prudential Financial Inc Portfolio

Follow Prudential Financial Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Prudential Financial Inc, based on Form 13F filings with the SEC.

News

Stay updated on Prudential Financial Inc with notifications on news.